Get started
Photocure $PHO.OL trade above last major resistance on US patentPatent covering the use of Blue Light Cystoscopy (BLC®) with Hexvix as neoadjuvant* therapy in the treatment of bladder cancer in patients who are scheduled for a cystectomy. Early stage study results have shown an antitumor effect and induced systemic immune effects of hexaminolevulinate (HAL) and blue light in an orthotopic model of rat bladder cancer. Photocure has the intention to further investigate Hexvix for its therapeutic effect and the patent is a result of Photocure’s continued focus on securing intellectual property rights for its research results and pipeline activities. The patent was issued on 11 February 2020 and will expire in December 2036. * Neoadjuvant therapy: treatment (such as chemotherapy) administered before primary cancer treatment (such as surgery) to enhance the outcome of primary treatment Photocure OSL:PHO IR news release: photocure.com
OSL:PHOLong
by savepiginvest
Can tecnical pattern push the stock back even with bad sentimentTO ME technically there is a lot off positive long term signs here. My challenge will be WHEN, at what price exactly to enter long. What do you guys think? should i enter at 26 and say good is good? or do you guys think i should try to hitt at a lower level? whe have seen eraligher that the right shoulder might be a little lower, but weeve allso seen it higher for this stock. And what do you think if one buys at 26 and it crosses down throught 25. Is that a sign for a quick temporary sell? Tell me in the coment section bellow! Fundamental analysis will probably play a big role annyhow. This is not a complete analysis. BUT the technical patterns are verry bright clare to the eye. The stock tends to never trend below theese levels we are now closing in at, at 26-24. Ive waitet since about november to see the stock at theese levels and im now getting verry happy that the stock is moving exactly following the pattern i drew upp in november. With head and choulders on the 4h and day chart. The tecnical aspects that counts for a medium time frame rend uppwards is: - first of all the history repeating itself with the head and sholders. - History repeating itself with head en shoulders - at theese same VERRY STRONG support levels at 25-26 (Look at volume profile also). - RSI bellow critical lavels with the first shoulder in the pattern. Here annyway, i am not shure if we now will se a crossing of critical levels again. My thought for now ist that i will not put to much weight om the RSI pussition between now-and possibly lower levels. It is low allready, so if we would see 26 price levels with the non-crossing RSI i would personally still see it as a cualified time to buy. Mabye look intraday to se if i can hit som lower level spike down under 26.. - Last B was 15 feb 2016, before that 07 may 2012, before that 02 may 2009. SO.. in thought of the time we see some pattern here. now its 10 feb 2020. So we would look to buy in the time between now and end of may, 4 years after last price at theese levels. Against: - One should not underestimate the possibility of in mowing down the support at 25, with allso day bars or intraday bars spiking well below these lewels down to for example 22,5. Around time for by i would follow news that might come out that can push it further down than the 25 levels. If i have bought at 26, and it pushes down to 25 i will sitt. Crossing down at 25 i will probably sell and wait for clearer signs of my tecnical (positive) factors to show themselves. Allso see some positive days with increasing wolume to get confirmation that we ar not going away from the historical trend or setteling bellow the heavy supports down there. TO ME technically there is a lot off positive long term signs here. My challenge will be WHEN, at what price exactly to enter long. What do you guys think? should i enter at 26 and say good is good? or do you guys think i should try to hitt at a lower level? whe have seen eraligher that the right shoulder might be a little lower, but weeve allso seen it higher for this stock. And what do you think if one buys at 26 and it crosses down throught 25. Is that a sign for a quick temporary sell? Tell me in the coment section bellow!
OSL:NHYLong
by Mort1
4
Yara International (YAR) | Looks Promising!Hi, Yara International ASA is a Norwegian chemical company. Its largest business area is the production of nitrogen fertilizer, however, it also encompasses the production of nitrates, ammonia, urea and other nitrogen-based chemicals. Some fundamental pros & cons: + Under the fair value. + A lot of insiders buying. + Yara and IBM launch an open collaboration for farm and field data to advance sustainable food production. - A bit high debt. Technical criteria: 1. The trendline third touch should act as support. 2. A strong orange horizontal price zone is printed several yearly highs and lows. 3. Fibonacci Retracement 62% acting as a support level. 4. Monthly EMA100 acting as support. Technically, I can see that the long-term growing platform is pretty solid, it stays between 317-340. Do your own research about fundamentals, company potential, valuation numbers and etc. Do not forget that perfect investing consists of good fundamentals (you have to make your own research) and you need a good buying area (you have it)! Line chart: Regards, Vaido
OSL:YARLong
by VaidoVeek
4
Waiting for a new buy posLooking for a new buy position. In Marts 2018 Frontline hit an all time low and after that a new uptrend have started. Atm its on its way down after a 101 % gain in the last 4 month ( Sep okt nov dec ) the normal drop with Frontline since the uptrend , is 70-110 % gain following a drop of 25-40 % and as of today it have dropped +/- 27 % so im thinking it gonna drop some more and maybe even alittel more then it use to becouse as you all know we have a virus fra china going on and that have a impact on almost all stocks, so we have to keep that in mind aswell befor making a buy or thinking omg its down 42 insted of the normal MAX 40 % as you see , the RSI and the MACD is not bullish but bearish ( so its NOT a buy atm ) as you also can see, we have higher highs and lower lows and its holing that patterns pretty nicely! As of now , im only making this cart to keep up with my already investet stock in Frontline and gonna jump in again when i see a turning point. Fell free to comment - we all are here with diff idears and mind set Disclaimer : i have this stock and im long and waiting for a new buy position.
OSL:FROLong
by SimpleinvestMarttin
1
American cancer vaccine patent boost $PCIB.OL over falling wedgePCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines Oslo (Norway), 21 January 2020 – PCI Biotech OSL:PCIB , a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines. Cytokines are small proteins that are involved in cell signaling, and that are very important in the immune system, modulating both cell-based and humoral immune responses. The combination of cytokines with PCI Biotech’s vaccine technology, fimaVacc, has been shown to be effective for enhancing cellular immune responses that are important for the effect of therapeutic vaccines. The now granted US patent gives broad coverage for the combination of various cytokines with the fimaVacc technology. There are many vaccines under development utilising cytokines to elicit immune responses. The US patent granted today is important for PCI Biotech’s development strategy, as it supplements our ability to generate an internal future vaccine pipeline, in addition to bringing value for the fimaVacc technology in partnering efforts, said Per Walday, CEO of PCI Biotech. As part of PCI Biotech’s strategy for applying the PCI-technology for therapeutic cancer vaccines, several global patent applications were filed in 2013 and 2014. Today’s granted US patent secure protection until 2035 and this patent application is still pending in Europe and key Asian markets. Press release direct URL: pcibiotech.no
OSL:PCIB
by savepiginvest
EQUINOR (EQNR) | Important Signs For Further Growth!Hi, Equinor ASA , an energy company, explores for, produces, transports, refines and markets petroleum and petroleum-derived products, and other forms of energy in Norway and internationally. Fundamental pros: 1. Trading below its fair value. 2. Good PE and PEG ratio. 3. Earnings are forecasted to grow. 4. A lot of insider buying. Technical pros: The correction, which started at the end of 2018, has started to show some positive signs for further growth. 1. The price has made a breakout from the down-trendline aka counter-trendline. Counter-trendlines breakouts are a pretty powerful tool to follow, especially when we have a really strong starting platform as Equinor has it at the moment. 2. Actually, the price made a breakout a couple of weeks ago and it has already retest it and again, it got a rejection upwards - the trendline which worked previously as resistance becomes support. 3. The trendline starts to work as support and there are also Weekly EMA 200 and Monthly EMA 50 which also should act as support levels. So, we have a pretty solid support level under the current price which is very good considering the breakthrough the counter-trendline. To show that mentioned "strong starting platform", we have to dig into the Monthly timeframe: The price got a pretty amazing rejection from a super-strong price level, it stays between ~150-160. A lot of criteria matched almost perfectly (strong support, AB=CD, Channel projection, Fibonacci golden ratio, EMA) and the rejection formed the strongest candlestick pattern ever lived (massive hype :D) - Monthly timeframe "Morning Star" has formed around the strong area! It depends on your investment horizon but the good entry should stay between the current price, 173, to 160 (in case it makes a tiny correction) but as said previously - luckily we have strong support just below the current price. The first target is around the psychological number 200 which should offer us about 17-20 percent profit. Do your own research and if this matching with mine then you are ready to go! Please, take a second and support my effort by hitting the "LIKE" button, it is my only FEE from You! Best regards, Vaido
OSL:EQNRLong
by VaidoVeek
LERØY SEAFOOD (LSG) | Strong Fundamentally & Technically!Hi, Lerøy Seafood Group produces, processes, markets, and distributes fresh, frozen, and smoked seafood products in Norway. It shows pretty good value numbers, it is way undervalued, insiders (CEO) have bought the stock recently (actually yesterday) and etc. Fundamentally, Lerøy Seafood looks quite good and most importantly, technically as well. There is a perfect area where you can invest or reinvest to Lerøy Seafood, the area consists of: 1) Weekly EMA200 2) Monthly EMA50 3) The round number 50 4) Channel projection 5) 2x AB=CD 6) Fibonacci Extensions 7) Fibonacci retracement 38%, pulled from all-time low to all-time high. 8) The trendline since 2012, historically, it is worked perfectly as support 9) 2016 high They all should work as support levels, adding these criteria together gives us a strong support area between 48 - 52.5 , which is also technically a good area to buy Lerøy Seafood. The first target stays around 60 which is approximately +20%. Do your own research and if this matching with mine then you are ready to go! Please, take a second and support my effort by hitting the "LIKE" button, it is my only FEE from You! Best regards, Vaido
OSL:LSGLong
by VaidoVeek
1
PCI Biotech $PCIB.OL top 10 hot nordic stocks @veckansaffarer www.va.se finansavisen.no PCI Biotech OSL:PCIB is a biopharmaceutical company focusing on development and commercialisation of novel therapeutic solutions for improved treatment of cancer patients through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that can be used to unlock the true potential of a wide array of therapeutic modalities. The company is applying PCI to three distinct anticancer paradigms: • fimaCHEM – enhancement of chemotherapeutics for localised treatment of cancer • fimaVACC – enhanced T-cell induction for therapeutic vaccination • fimaNAc – nucleic acid therapeutics delivery The company’s lead fimaCHEM programme consists of a pivotal clinical study with registration intent of Amphinex® in bile duct cancer, an orphan indication with a high-unmet need and without approved products. Clinical proof-of-concept has been achieved in the fimaVACC programme, which applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines. The fimaNAc programme utilises the triggered endosomal release to provide effective intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising class of therapeutics.
OSL:PCIB
by savepiginvest
Bakkafrost, at the top of everything?Bakkafrost looks to be closing to the top of everything, IF previous pattern repeats itself. From just half a year ago Bakkafrost could be bought at around 440 NOK followed by a steady rise to a current 640 NOK. This is a staggering 50% increase in just half a year. That alone is not the only factor Bakkafrost has against a further rise. We also see that if the Impulse Elliot Waves repeats itself we are close to an A,B,C elliot correction. Or even an A,B,C,D correction. But time will show. Also Bakkafrost is getting very close to the top of the parallel channel its been impulsing in for close to a year now. If it breaks the channel, thats another case. But I find that unlikely but still possible. So basing it on previous Elliot Waves. We see that impulse wave 1,2,3,4 and 5 was completed. Then the Elliot A,B to C was completed. Immediately after that Bakkafrost continued into a new set of impulse waves, 1,2,3,4 and the fifth close to completing. Still some more room for a further rise, but again, if the pattern repeats itself, we are likely to soon see the correction in Bakkafrost. I am short
OSL:BAKKAShort
by Stilster
BerGenBio $BGBIO.OL rallies amid Norwegian biotech optimismBerGenBio OSL:BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal. Sponsored analyst summary: www.trinitydelta.org Twitter: twitter.com Investor Relations: www.bergenbio.com
OSL:BGBIOLong
by savepiginvest